Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria

被引:91
作者
Fu, Hongyuan [1 ,2 ,3 ]
Zheng, Jun [1 ,2 ,3 ]
Cai, Jianye [1 ,2 ,3 ]
Zeng, Kaining [1 ,2 ,3 ]
Yao, Jia [1 ,2 ,3 ]
Chen, Liang [1 ,2 ,3 ]
Li, Hui [1 ,2 ,3 ]
Zhang, Jiebin [1 ,2 ,3 ]
Zhang, Yingcai [1 ,2 ,3 ]
Zhao, Hui [1 ,2 ,3 ]
Yang, Yang [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Organ Transplantat Res Ctr Guangdong Prov, Affiliated Hosp 3, Organ Transplantat Inst,Dept Hepat Surg, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Organ Transplantat Res Ctr Guangdong Prov, Affiliated Hosp 3, Organ Transplantat Inst,Liver Transplantat Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, Key Lab Liver Dis Biotherapy & Translat Med Guang, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; Systemic immune-inflammatory index; Liver transplantation; NEUTROPHIL-LYMPHOCYTE RATIO; CANCER; IMPACT;
D O I
10.1159/000489807
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: There is growing evidence that the systemic immune-inflammation index (SII), a novel prognostic biomarker based on peripheral lymphocyte, neutrophil, and platelet counts, is associated with poor prognosis for several tumors. However, the prognostic value of SII in patients with hepatocellular carcinoma (HCC) who undergo liver transplantation (LT) remains unclear. The aim of this study was to determine the correlation between SII and prognosis in these patients. Methods: This retrospective study involved 150 patients with HCC who underwent LT within the Hangzhou criteria. The optimal cut-off value was determined by receiver-operating characteristic (ROC) curve analysis to stratify the patients into those with a high SII and those with low SII. The Kaplan-Meier method and the Cox proportional hazards model were used to evaluate the prognostic value of SII. Finally, we calculated the area under the ROC curve to compare the prognostic power of SII, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). Results: Patients were divided into high SII (>= 226) and low SII (< 226) groups. Five-year overall survival (OS) was lower in the high SII group than in the low SII group (56.1% vs. 82.4%, p = 0.002). SII >= 226 x 109/L, maximum tumor size > 5 cm, microvascular invasion, and poor differentiation were independent prognostic factors for OS. However, SII did not predict 5-year recurrence-free survival (high vs. low SII: 64.1% vs. 78.4%, p = 0.073). The area under the ROC curve was greater for SII than for PLR, NLR, and MLR. Conclusions: Preoperative SII may be a powerful prognostic biomarker in patients with HCC who undergo LT within the Hangzhou criteria. SII is superior to PLR, NLR, and MLR for prediction of OS in these patients. (c) 2018 The Author(s) Published by S. Karger AG, Basel.
引用
收藏
页码:293 / 301
页数:9
相关论文
共 32 条
[1]   Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study [J].
Bains, Simer J. ;
Mahic, Milada ;
Myklebust, Tor Age ;
Smastuen, Milada Cvancarova ;
Yaqub, Sheraz ;
Dorum, Liv Marit ;
Bjornbeth, Bjorn Atle ;
Moller, Bjorn ;
Brudvik, Kristoffer Watten ;
Tasken, Kjetil .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2501-+
[2]   The platelet contribution to cancer progression [J].
Bambace, N. M. ;
Holmes, C. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (02) :237-249
[3]   Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma [J].
Chew, Valerie ;
Chen, Jinmiao ;
Lee, Deming ;
Loh, Evelyn ;
Lee, Joyce ;
Lim, Kiat Hon ;
Weber, Achim ;
Slankamenac, Ksenija ;
Poon, Ronnie T. P. ;
Yang, Henry ;
Ooi, London Lucien P. J. ;
Toh, Han Chong ;
Heikenwalder, Mathias ;
Ng, Irene O. L. ;
Nardin, Alessandra ;
Abastado, Jean-Pierre .
GUT, 2012, 61 (03) :427-438
[4]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[5]   Cancer-related inflammation and treatment effectiveness [J].
Diakos, Connie I. ;
Charles, Kellie A. ;
McMillan, Donald C. ;
Clarke, Stephen J. .
LANCET ONCOLOGY, 2014, 15 (11) :E493-E503
[6]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[7]   Dual Roles for Immunity in Gastrointestinal Cancers [J].
Ferrone, Cristina ;
Dranoff, Glenn .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (26) :4045-4051
[8]   Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database [J].
Freeman, Richard B. ;
Mithoefer, Abigail ;
Ruthazer, Robin ;
Nguyen, Khanh ;
Schore, Anthony ;
Harper, Ann ;
Edwards, Erick .
LIVER TRANSPLANTATION, 2006, 12 (10) :1504-1511
[9]   Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib [J].
Gardini, Andrea Casadei ;
Scarpi, Emanuela ;
Faloppi, Luca ;
Scartozzi, Mario ;
Silvestris, Nicola ;
Santini, Daniele ;
de Stefano, Giorgio ;
Marisi, Giorgia ;
Negri, Francesca V. ;
Foschi, Francesco Giuseppe ;
Valgiusti, Martina ;
Ercolani, Giorgio ;
Frassineti, Giovanni Luca .
ONCOTARGET, 2016, 7 (41) :67142-67149
[10]   Tumor-Associated Neutrophils: New Targets for Cancer Therapy [J].
Gregory, Alyssa D. ;
Houghton, A. McGarry .
CANCER RESEARCH, 2011, 71 (07) :2411-2416